bioAffinity Technologies Celebrates Initial Success of CyPath® Lung
b>bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), dedicated to advancing noninvasive cancer detection and lung disease diagnostics, has unveiled remarkable outcomes from its recent pilot marketing program for the CyPath® Lung test. Focused on enhancing patient care, the Texas beta launch has seen over 600 tests delivered so far in 2024, signaling a promising start for the company's innovative diagnostic solution.
Growth Achievements in 2024
Leaders at bioAffinity Technologies expressed great enthusiasm over the significant sales growth achieved thus far. Maria Zannes, President and CEO of the company, emphasized the importance of CyPath® Lung as physicians increasingly integrate its use into their medical practices. As part of their commitment to serve veterans, the company is gearing up to introduce CyPath® Lung into veteran and military medical systems.
Continuous Sales Progress
Year-on-year growth is bolstered by CyPath® Lung’s recent inclusion in the U.S. Federal Supply Schedule (FSS), aiming to ensure accessibility to veterans and active military personnel utilizing government health systems. This proactive approach underscores the company's dedication to facilitating early detection of lung cancers, thus improving patient outcomes.
Impressive Diagnostic Metrics
CyPath® Lung stands out for exhibiting an impressive 92% sensitivity and 87% specificity in high-risk patients, particularly those with nodules below 20 millimeters. These statistics reveal that over half of the patients tested were diagnosed with early-stage I or II lung cancer. Remarkably, the test has successfully detected various lung cancer types, including adenocarcinoma, squamous cell carcinoma, and small cell lung cancer.
Positive Insights from Medical Professionals
Alongside these promising metrics, physicians have showcased excitement about the findings from a recent peer-reviewed economic study. This analysis, conducted by respected pulmonologists, estimated significant savings—totaling $379 million—for the Medicare population if CyPath® Lung had been the standard care diagnostic test. Therefore, for private insurance patients, potential savings exceeded $895 million, illustrating the broader impact of this revolutionary technology.
Future Endeavors for CyPath® Lung
As adoption of CyPath® Lung expands, testimonials from doctors highlight the importance of early detection, which is critical for patients potentially facing lung cancer. Zannes reflected on the profound emotional impact of these early detection stories, reinforcing the mission to improve patient care through enhanced lung cancer diagnosis and treatment methods.
Collaborations and Community Engagement
Looking ahead, bioAffinity Technologies is eager to ramp up marketing efforts in collaboration with key opinion leaders. By enhancing visibility around CyPath® Lung, the company aims to capture a larger segment of the lung cancer diagnostic market. The strategic expansion is poised to play a crucial role in providing reassurance to patients at risk and further establishing the test’s value in clinical settings.
About CyPath® Lung
CyPath® Lung utilizes advanced flow cytometry and artificial intelligence (AI) to pinpoint cell populations in patient sputum that may indicate malignancy. This automated and efficient analytical process allows healthcare professionals to assess the presence of cancer accurately while determining if a patient is cancer-free.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. is committed to resolving the pressing need for noninvasive diagnostics that effectively identify early-stage cancer and respiratory diseases. The company is paving the way for broad-spectrum cancer treatment options, focusing on the promising results from its flagship product, CyPath® Lung, which facilitates high sensitivity and specificity in lung cancer detection.
Frequently Asked Questions
What is CyPath® Lung?
CyPath® Lung is a noninvasive diagnostic test developed by bioAffinity Technologies to detect early-stage lung cancer using advanced flow cytometry and AI.
How has the Texas beta launch performed?
The Texas beta launch has achieved over 600 test deliveries in 2024, indicating strong initial market demand and acceptance among healthcare professionals.
What are its diagnostic metrics?
CyPath® Lung exhibits 92% sensitivity and 87% specificity, particularly in patients with nodules under 20 millimeters, showcasing its effectiveness in early-stage detection.
What benefits could result from its use?
Utilizing CyPath® Lung could lead to significant cost savings for healthcare systems while improving patient outcomes, especially within the Medicare demographic.
What are future plans for CyPath® Lung?
bioAffinity Technologies aims to expand marketing efforts and collaborations to enhance the adoption of CyPath® Lung, especially within veteran and military medical systems in 2025.
